Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) ranks among the most oversold biotech stocks to invest in. On November 3, Mizuho maintained its Neutral rating for Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and reduced its price target from $24 to $19. Despite encouraging early results from Empaveli’s launch in C3G/IC-MPGN indications, Mizuho attributed the revision largely to ongoing growth issues with Syfovre, Apellis’ medication for eye disease.

In Q3 2025, Syfovre’s revenue totaled $150.9 million, a minor decrease from $152.0 million in Q3 2024. Despite this minor fall, the company reported a 4% quarter-over-quarter gain in injections. Apellis Pharmaceuticals Inc. stated that SYFOVRE retains over 60% market share in the GA treatment area, with 52% of new patient starts in Q3 2025.

Mizuho has cut its Syfovre revenue projections, now projecting a peak annual revenue of about $800 million, 25–30% lower than the consensus estimates.

Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds to treat diseases with high unmet needs.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

This article is originally published at Insider Monkey.